Positive results reported for SURF-201 in treatment of postop pain, inflammation
Click Here to Manage Email Alerts
SURF-201 met its primary endpoints in a phase 2 trial investigating the therapy in the treatment of post-cataract surgery pain and inflammation, according to a press release from Surface Ophthalmics.
In a trial of 91 patients, SURF-201 (betamethasone 0.2%) demonstrated complete clearance of anterior chamber cells, a marker for inflammation, at day 8 and day 15 (P = .01 and P = .001, respectively). For the secondary endpoint, almost 90% of patients were pain-free at day 15. Further, the treatment was safe and well-tolerated, and IOP did not increase more than 10 mm Hg from baseline or exceed 22 mm Hg.
“This is a critical point in time for Surface Ophthalmics — over the coming months, we will be moving forward with SURF-201 as well as advancing our pipeline of SURF-100 (chronic dry eye) and SURF-200 (episodic dry eye) into phase 2 trials,” Kamran Hosseini, MD, PhD, Surface Ophthalmics president and CEO, said in the release. “Based on the data we received from this study, we feel even more confident that our building block approach to product development will continue to demonstrate positive results and allow us to fully recognize the potential of our robust pipeline to offer innovative solutions for unmet patient needs in the ophthalmic space.”
SURF-201 is the first ophthalmic solution in the U.S. to use betamethasone and the first preservative-free unit dose therapy for postoperative pain and inflammation.
Read more about
Click Here to Manage Email Alerts